Frankfurt
28.08.26 | 15:25
15,700 Euro
+2,61 % +0,400
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 13.08. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 13 | SEC Filings | ||
| 23.06. | Fortress Biotech, Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 14.05. | Fortress Biotech, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| FORTRESS BIOTECH INC PREF Aktie jetzt für 0€ handeln | |||||
| 14.05. | Fortress Biotech GAAP EPS of $2.82, revenue of $16.04M misses by $0.3M | 3 | Seeking Alpha | ||
| 14.05. | Fortress Biotech, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 14.05. | Fortress Biotech, Inc.: Fortress Biotech Reports First Quarter 2026 Financial Results and Recent Corporate Highlights | 805 | GlobeNewswire (Europe) | ZYCUBO approved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics closed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million... ► Artikel lesen | |
| 31.03. | Fortress Biotech GAAP EPS of -$0.07 misses by $0.39, revenue of $63.26M misses by $10.08M | 6 | Seeking Alpha | ||
| 31.03. | Fortress Biotech, Inc.: Fortress Biotech Reports 2025 Financial Results and Recent Corporate Highlights | 813 | GlobeNewswire (Europe) | ZYCUBOapproved by FDA to treat Menkes disease in the United States; Fortress subsidiary Cyprium Therapeutics sold its Rare Pediatric Disease Priority Review Voucher (PRV) for gross proceeds of $205... ► Artikel lesen | |
| 31.03. | Fortress Biotech, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 30.03. | Fortress Biotech, Inc.: Fortress Biotech's Subsidiary Cyprium Therapeutics Closes Sale of Rare Pediatric Disease Priority Review Voucher for $205 Million | 426 | GlobeNewswire (Europe) | MIAMI, March 30, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced the closing... ► Artikel lesen | |
| 23.02. | Fortress Biotech, Inc.: Fortress Biotech's Subsidiary Cyprium Therapeutics Enters into Agreement to Sell Rare Pediatric Disease Priority Review Voucher for $205 Million | 548 | GlobeNewswire (Europe) | MIAMI, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that Cyprium... ► Artikel lesen | |
| 16.01. | Weekly Buzz: Lyra Therapeutics Slashes Jobs; FDA Okays Fortress Biotech's ZYCUBO; Boston Scientific To Acquire Penumbra; BriaCell Therapeutics On Watch | 969 | AFX News | NEW BRUNSWICK (dpa-AFX) - This week, the biotech sector saw a steady stream of high-impact news, including a major workforce reduction and a fresh round of regulatory clearances spanning diabetes... ► Artikel lesen | |
| 13.01. | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Approval of ZYCUBO (copper histidinate), the First and Only Approved Treatment for Menkes Disease in the United States | 966 | GlobeNewswire (Europe) | Rare Pediatric Disease Priority Review Voucher (PRV) granted by FDA at approval to be transferred from Sentynl Therapeutics to Cyprium Cyprium eligible to receive tiered royalties and up to $129 million... ► Artikel lesen | |
| 14.11.25 | Fortress Biotech, Inc.: Fortress Biotech Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights | 956 | GlobeNewswire (Europe) | Total net revenue increased 20.5% to $17.6 million for third quarter of 2025 compared to the third quarter of 2024 Fortress subsidiary Checkpoint Therapeutics acquired by Sun Pharma; Fortress received... ► Artikel lesen | |
| 21.10.25 | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce First Patients Dosed in Crystalys Therapeutics' Global Phase 3 Trials of Dotinurad for the Treatment of Gout | 413 | GlobeNewswire (Europe) | MIAMI, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Urica Therapeutics, Inc. ("Urica" or the "Company"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") subsidiary, today announced that Crystalys Therapeutics... ► Artikel lesen | |
| 01.10.25 | Fortress Biotech, Inc.: Fortress Biotech and Subsidiary Urica Therapeutics Announce Crystalys Therapeutics' $205 Million Series A Financing | 260 | GlobeNewswire (Europe) | Dotinurad is a next-generation URAT1 inhibitor in two Phase 3 clinical trials with potential for best-in-class safety and efficacy Urica sold dotinurad to Crystalys Therapeutics in 2024 in exchange... ► Artikel lesen | |
| 01.10.25 | Fortress Biotech, Inc.: Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101 | 319 | GlobeNewswire (Europe) | MIAMI, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") and its majority-owned subsidiary, Cyprium Therapeutics, Inc. ("Cyprium"), today announced that the U.S.... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| STRYKER | 285,30 | -0,07 % | Do Options Traders Know Something About Stryker Stock We Don't? | ||
| REGENERON PHARMACEUTICALS | 682,40 | -0,41 % | Veeva Systems: Veeva Vault CRM Selected by Regeneron | Leading biopharma company selects agentic CRM for life sciences to generate Commercial EvidencePLEASANTON, Calif., Aug. 25, 2026 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced... ► Artikel lesen | |
| VIKING THERAPEUTICS | 27,850 | +0,36 % | Viking Therapeutics Has $502 Million in Cash and 1 Big Catalyst Left in 2026 -- Is That Enough? | ||
| INTELLIA THERAPEUTICS | 11,220 | +0,90 % | Cathie Wood's ARK buys Intellia stock, sells Roblox | ||
| TEMPUS AI | 55,25 | -0,04 % | Tempus AI (TEM) Jumped on Moderna's Melanoma Win. Did its $1.5B Personalis Acquisition Just Get Validated? | ||
| NUREXONE BIOLOGIC | 0,349 | +4,18 % | Keine von der FDA zugelassene Exosomentherapie: Warum NurExone eine große Marktchance adressiert | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,242 | +3,11 % | PacBio Appoints Mark Van Oene as President and Chief Executive Officer | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) ("PacBio"), a leading developer of high-quality, highly accurate sequencing solutions,... ► Artikel lesen | |
| IMMUNITYBIO | 6,880 | -1,01 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| GINKGO BIOWORKS | 6,064 | +0,66 % | Ginkgo Bioworks Reports First Quarter 2026 Financial Results, Completes Divestiture of Biosecurity and Continues to Scale Autonomous Lab | Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business
BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,330 | -0,30 % | Recursion Pharmaceuticals: Recursion Reports Second Quarter Financial Results; Genentech Options First Neuroscience Target into Early Discovery Program | Genentech advanced the collaboration's first neuroscience target into a joint early discovery program, providing early evidence that Recursion's platform can generate novel, biologically validated... ► Artikel lesen | |
| IOVANCE BIOTHERAPEUTICS | 6,910 | -0,29 % | TD Cowen raises Iovance Biotherapeutics price target on sales outlook | ||
| CYTOMX THERAPEUTICS | 2,875 | +3,27 % | CytomX Therapeutics Inc.: CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan ("Varseta-M") for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC) | - Fast Track Designation follows encouraging Phase 1 data that were previously reported for R/R mCRC - - Potential Varseta-M monotherapy registrational study in R/R mCRC planned for initiation in... ► Artikel lesen | |
| SANA BIOTECHNOLOGY | 3,930 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Reports Second Quarter 2026 Financial Results and Business Updates | Continued progress toward starting SC451 Phase 1/2 trial, including GLP toxicology studies, SC451 process transfer to the contract manufacturer, and clinical trial readiness Continued progress toward... ► Artikel lesen | |
| BIOMEA FUSION | 1,735 | 0,00 % | Biomea Fusion, Inc.: Biomea Fusion Announces Completion of Enrollment in COVALENT-211 Phase II Trial of Icovamenib in Insulin-Deficient Type 2 Diabetes | Topline 26-week primary endpoint data from COVALENT-211 in insulin deficient type 2 diabetes ("T2D") patients who are not achieving glycemic targets despite antihyperglycemic medications anticipated... ► Artikel lesen | |
| LIANBIO | - | - | LianMedical (Formerly Known as LianBio) Announces Completion of Merger Between LianBio and LianMedical | • Combined company to operate as LianMedical
• LianMedical to focus on advancing patient access to innovative medical technologies in China and other Asia Pacific markets
PRINCETON, N.J. & SHANGHAI--(BUSINESS... ► Artikel lesen |
Das Unternehmen FORTRESS BIOTECH INC PREF kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 15,700 Euro und damit +2,61 % im Plus. Beim derzeitigen Kurs ergibt sich, basierend auf einer gesamten Ausschüttung von 0,00 Euro in den vergangenen 12 Monaten, eine Dividendendrendite von 0,00 %.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu FORTRESS BIOTECH INC PREF finden Sie auf Wallstreet Online.